Salesforce Remains Down But Turning Positive: 100%+ Returns Lie Ahead According to This Analyst

Photo of Alex Sirois
By Alex Sirois Published

Quick Read

  • Needham's Scott Berg carries a $400 price target on CRM, implying 117% upside, anchored by Agentforce ARR growing 205% YoY to $1.2B.

  • Among enterprise software peers, ORCL shows the widest analyst-implied upside at ~91%, while HUBS has suffered the steepest one-year decline at over 54%.

  • Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Salesforce didn't make the cut. Grab the names FREE today.

Salesforce Remains Down But Turning Positive: 100%+ Returns Lie Ahead According to This Analyst

© Noam Galai / Getty Images Entertainment via Getty Images

Salesforce (NYSE:CRM | CRM Price Prediction) currently trades at $184.02, while the Wall Street consensus price target sits at $241.72. That implies roughly 31% upside from current levels.

Salesforce sells cloud-based CRM software and has repositioned itself as the operating system for what CEO Marc Benioff calls the “agentic enterprise,” with Agentforce and Data 360 driving growth. Wall Street has spent 2026 debating whether AI monetization can reaccelerate organic growth. The stock has been punished even as earnings kept beating, which is why the gap matters.

The Selloff That Erased a Year of Gains

CRM is down 30.17% year to date and 28.15% over the last year, sliding from the mid-$240s in late 2025 to a 52-week low of $146.32.

Two catalysts drove the decline. Morgan Stanley downgraded on a slower-than-expected inflection point for organic revenue growth, flagging that Agentforce accounts for only 2.6% of total revenue. Noncurrent debt jumped from $10.4B to $39.3B to fund a $25 billion accelerated share repurchase, which pulled the diluted share count from 970 million to 871 million but stacked leverage on top of Informatica integration risk.

Why Analysts Aren’t Blinking, and One Sees 100%+ Upside

The bull thesis rests on Agentforce monetizing faster than the market credits. Q1 FY27 EPS came in at $3.88 versus a $3.13 estimate, a 24.08% beat and the fifth consecutive quarter of exceeding expectations. Revenue grew 13.3% year over year to $11.13 billion, Agentforce ARR reached $1.2 billion (up 205% YoY), and combined Agentforce plus Data 360 ARR hit nearly $3.4 billion. Management raised FY27 revenue guidance to $45.9 billion to $46.2 billion and reaffirmed the $63 billion FY30 revenue target.

Of the 52 analysts covering CRM, the ratings split is:

  • Strong Buy: 6
  • Buy: 34
  • Hold: 10
  • Sell: 0
  • Strong Sell: 2

Institutional buying reinforced the bull view: Bank of America added 2.56 million shares in Q1 to a position now worth roughly $2.19 billion.

The most aggressive call belongs to Scott Berg at Needham & Co., who carries a $400 target, the highest active fundamental price target on the Street. Against a current price near $184, that implies over 117% upside. Berg’s thesis rests on three pillars: Agentforce ARR crossing well past $1 billion, consumption monetization via Flex Credits, and Slack evolving into the primary agentic layer for enterprise workflows. Flex Credits reprice AI usage to scale with adoption. If that curve holds, Berg’s math is aggressive rather than fanciful.

How CRM Stacks Up Against Enterprise Software Peers

ServiceNow (NYSE:NOW) trades at $111.23 versus a $140.25 consensus target, about 26% upside. NOW is down 27.4% YTD and 41% over one year despite delivering 24% Q2 revenue growth and crossing $1 billion in ACV for ServiceNow AI.

Oracle (NYSE:ORCL) trades at $129.87 against a $248.15 consensus target, roughly 91% upside and the largest gap in the group. ORCL is down 32.7% YTD and 48.2% over one year, punished for $55.7 billion in FY26 capex and deeply negative free cash flow tied to AI datacenter buildout, even as RPO surged 363% to $638 billion.

HubSpot (NYSE:HUBS) trades at $237.36 against a $273.96 target, only about 15% upside. HUBS is down 40.9% YTD and 54.3% over one year, the worst decline in the group.

The largest analyst-implied upside sits with Oracle at roughly 91%. Against that peer set, CRM’s 31% consensus upside looks moderate, but Berg’s $400 outlier puts it in the 100%+ conversation with cleaner cash flow economics.

What the Data Shows

Current price is $184.02, consensus PT $241.72, implied upside near 31%. Fifty-two analysts cover the stock. CRM trades roughly 31% below its 52-week high of $267.75, at a forward P/E of about 14x.

Year-to-date, CRM is down 30.17% against a +9.55% gain for the S&P 500. Recent action has flipped: shares are up 12.44% over the past week and 12.74% over the past month. Reddit sentiment on r/stocks shifted from bearish scores of 28-38 in mid-July to bullish readings of 68-72 by late July.

The Bottom Line

The bull case holds if Agentforce is real and consumption monetization plus Flex Credits drive multi-year reacceleration. In that scenario, cRPO of $33.6 billion (up 14%) is a floor, the $50 billion buyback authorization compounds EPS, and Berg’s $400 target becomes defensible.

The bear case dominates if Agentforce at 2.6% of revenue is too small to move the needle before organic growth decelerates, if Informatica integration disrupts execution, or if the debt ramp bites in a higher-for-longer rate environment. Microsoft, ServiceNow, and Oracle are attacking the same enterprise agentic AI opportunity.

On balance, the consensus 31% upside looks reasonable, the recent bounce suggests sentiment is turning, and even partial validation of the Agentforce thesis would rerate the stock. Berg’s $400 target requires near-perfect execution across ARR growth, Slack monetization, and Flex Credits adoption, but it is no longer an obviously wrong bet.

Contact [email protected] for any questions or corrections.

Photo of Alex Sirois
About the Author Alex Sirois →

Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.

Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.

At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.

Continue Reading

Top Gaining Stocks

MRNA Vol: 87,315,627
COIN Vol: 22,740,003
FCX Vol: 29,776,620
ALB Vol: 3,308,526
EL Vol: 6,022,533

Top Losing Stocks

CTRA Vol: 73,319,495
SRE Vol: 5,176,593
EIX Vol: 3,946,409
AEP Vol: 5,247,385
CNP Vol: 7,823,794